Andrew is an internationally recognized authority in inflammatory skin disease and molecular dermatology, regarded as a leading voice in the integration of precision diagnostics and advanced therapeutics in clinical practice. His work sits at the intersection of immunodermatology, molecular diagnostics, and biologic innovation—shaping how dermatology defines, diagnoses, and treats chronic inflammatory disease.

With deep expertise in immune signaling pathways and gene-expression profiling, Andrew is at the forefront of translating molecular insights into actionable clinical strategies. He is a strong advocate for incorporating genomic diagnostics and AI-enabled decision support tools into routine dermatologic care, elevating disease stratification, therapeutic precision, and long-term outcomes in conditions such as atopic dermatitis, psoriasis, hidradenitis suppurativa, and other complex inflammatory disorders.

A published author in peer-reviewed journals and editorial advisory board member and is widely respected for advancing the dialogue around precision genomics, inflammatory disease endotyping, AI-supported diagnostics, and the future of dermatologic therapeutics.

In addition to his educational and research contributions, Andrew serves as President-Elect of the Society of Dermatology Physician Associates, where he provides national leadership on workforce development, policy advocacy, and the evidence-based integration of next-generation therapies and molecular diagnostics—solidifying his role as a transformative leader in modern dermatology.